Cargando…

The Protective Effect of Low-Dose Aspirin against Colorectal Cancer Is Unlikely Explained by Selection Bias: Results from Three Different Study Designs in Clinical Practice

BACKGROUND: We conducted three differently designed nested case–control studies to evaluate whether the protective effect of low-dose aspirin against colorectal cancer (CRC) is explained by selection bias. METHODS: Using a large validated UK primary care database, we followed different cohorts of pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Cea Soriano, Lucía, Soriano-Gabarró, Montse, García Rodríguez, Luis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948817/
https://www.ncbi.nlm.nih.gov/pubmed/27428004
http://dx.doi.org/10.1371/journal.pone.0159179
_version_ 1782443332320886784
author Cea Soriano, Lucía
Soriano-Gabarró, Montse
García Rodríguez, Luis A.
author_facet Cea Soriano, Lucía
Soriano-Gabarró, Montse
García Rodríguez, Luis A.
author_sort Cea Soriano, Lucía
collection PubMed
description BACKGROUND: We conducted three differently designed nested case–control studies to evaluate whether the protective effect of low-dose aspirin against colorectal cancer (CRC) is explained by selection bias. METHODS: Using a large validated UK primary care database, we followed different cohorts of patients, who varied in their demographic and clinical characteristics, to identify first ever cases of CRC. In Studies 1 and 2, two cohorts were followed, i) new users of low-dose aspirin at start of follow-up (N = 170,336 in Study 1, N = 171,527 in Study 2) and either ii) non-users of low-dose aspirin (Study 1, N = 170,336) or new users of paracetamol (Study 2, N = 149,597) at start of follow-up. In Study 3 a single cohort of individuals näive to low-dose aspirin at the start of observation was followed. Controls were selected using incidence sampling and logistic regression used to obtain an unbiased estimate of the incidence rate ratio (RR) with 95% confidence intervals (CIs). Low-dose aspirin exposure was analyzed ‘as-treated’ before the index date (CRC date for cases, random date for controls). RESULTS: In the three studies, median (maximum) follow-up was 5.1 (12), 5.8 (12) and 7.5 (13) years, respectively. 3033 incident CRC cases were identified in Study 1, 3174 in Study 2, and 12,333 in Study 3. Current use of low-dose aspirin was associated with a significantly reduced risk of 34%, 29% and 31% in the three studies, respectively; corresponding RRs (95% CIs) were 0.66 (0.60–0.73), 0.71 (0.63–0.80) and 0.69 (0.64–0.74). In each study, significantly reduced risks of CRC were seen when low-dose aspirin was used for primary or secondary cardiovascular disease prevention, in both sexes, and across all age groups evaluated. CONCLUSION: Low-dose aspirin is associated with a significantly reduced risk of CRC. The consistency of our findings across different studies makes selection bias an unlikely explanation.
format Online
Article
Text
id pubmed-4948817
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-49488172016-08-01 The Protective Effect of Low-Dose Aspirin against Colorectal Cancer Is Unlikely Explained by Selection Bias: Results from Three Different Study Designs in Clinical Practice Cea Soriano, Lucía Soriano-Gabarró, Montse García Rodríguez, Luis A. PLoS One Research Article BACKGROUND: We conducted three differently designed nested case–control studies to evaluate whether the protective effect of low-dose aspirin against colorectal cancer (CRC) is explained by selection bias. METHODS: Using a large validated UK primary care database, we followed different cohorts of patients, who varied in their demographic and clinical characteristics, to identify first ever cases of CRC. In Studies 1 and 2, two cohorts were followed, i) new users of low-dose aspirin at start of follow-up (N = 170,336 in Study 1, N = 171,527 in Study 2) and either ii) non-users of low-dose aspirin (Study 1, N = 170,336) or new users of paracetamol (Study 2, N = 149,597) at start of follow-up. In Study 3 a single cohort of individuals näive to low-dose aspirin at the start of observation was followed. Controls were selected using incidence sampling and logistic regression used to obtain an unbiased estimate of the incidence rate ratio (RR) with 95% confidence intervals (CIs). Low-dose aspirin exposure was analyzed ‘as-treated’ before the index date (CRC date for cases, random date for controls). RESULTS: In the three studies, median (maximum) follow-up was 5.1 (12), 5.8 (12) and 7.5 (13) years, respectively. 3033 incident CRC cases were identified in Study 1, 3174 in Study 2, and 12,333 in Study 3. Current use of low-dose aspirin was associated with a significantly reduced risk of 34%, 29% and 31% in the three studies, respectively; corresponding RRs (95% CIs) were 0.66 (0.60–0.73), 0.71 (0.63–0.80) and 0.69 (0.64–0.74). In each study, significantly reduced risks of CRC were seen when low-dose aspirin was used for primary or secondary cardiovascular disease prevention, in both sexes, and across all age groups evaluated. CONCLUSION: Low-dose aspirin is associated with a significantly reduced risk of CRC. The consistency of our findings across different studies makes selection bias an unlikely explanation. Public Library of Science 2016-07-18 /pmc/articles/PMC4948817/ /pubmed/27428004 http://dx.doi.org/10.1371/journal.pone.0159179 Text en © 2016 Cea Soriano et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Cea Soriano, Lucía
Soriano-Gabarró, Montse
García Rodríguez, Luis A.
The Protective Effect of Low-Dose Aspirin against Colorectal Cancer Is Unlikely Explained by Selection Bias: Results from Three Different Study Designs in Clinical Practice
title The Protective Effect of Low-Dose Aspirin against Colorectal Cancer Is Unlikely Explained by Selection Bias: Results from Three Different Study Designs in Clinical Practice
title_full The Protective Effect of Low-Dose Aspirin against Colorectal Cancer Is Unlikely Explained by Selection Bias: Results from Three Different Study Designs in Clinical Practice
title_fullStr The Protective Effect of Low-Dose Aspirin against Colorectal Cancer Is Unlikely Explained by Selection Bias: Results from Three Different Study Designs in Clinical Practice
title_full_unstemmed The Protective Effect of Low-Dose Aspirin against Colorectal Cancer Is Unlikely Explained by Selection Bias: Results from Three Different Study Designs in Clinical Practice
title_short The Protective Effect of Low-Dose Aspirin against Colorectal Cancer Is Unlikely Explained by Selection Bias: Results from Three Different Study Designs in Clinical Practice
title_sort protective effect of low-dose aspirin against colorectal cancer is unlikely explained by selection bias: results from three different study designs in clinical practice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948817/
https://www.ncbi.nlm.nih.gov/pubmed/27428004
http://dx.doi.org/10.1371/journal.pone.0159179
work_keys_str_mv AT ceasorianolucia theprotectiveeffectoflowdoseaspirinagainstcolorectalcancerisunlikelyexplainedbyselectionbiasresultsfromthreedifferentstudydesignsinclinicalpractice
AT sorianogabarromontse theprotectiveeffectoflowdoseaspirinagainstcolorectalcancerisunlikelyexplainedbyselectionbiasresultsfromthreedifferentstudydesignsinclinicalpractice
AT garciarodriguezluisa theprotectiveeffectoflowdoseaspirinagainstcolorectalcancerisunlikelyexplainedbyselectionbiasresultsfromthreedifferentstudydesignsinclinicalpractice
AT ceasorianolucia protectiveeffectoflowdoseaspirinagainstcolorectalcancerisunlikelyexplainedbyselectionbiasresultsfromthreedifferentstudydesignsinclinicalpractice
AT sorianogabarromontse protectiveeffectoflowdoseaspirinagainstcolorectalcancerisunlikelyexplainedbyselectionbiasresultsfromthreedifferentstudydesignsinclinicalpractice
AT garciarodriguezluisa protectiveeffectoflowdoseaspirinagainstcolorectalcancerisunlikelyexplainedbyselectionbiasresultsfromthreedifferentstudydesignsinclinicalpractice